ZA202402786B - Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis - Google Patents
Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosisInfo
- Publication number
- ZA202402786B ZA202402786B ZA2024/02786A ZA202402786A ZA202402786B ZA 202402786 B ZA202402786 B ZA 202402786B ZA 2024/02786 A ZA2024/02786 A ZA 2024/02786A ZA 202402786 A ZA202402786 A ZA 202402786A ZA 202402786 B ZA202402786 B ZA 202402786B
- Authority
- ZA
- South Africa
- Prior art keywords
- coated
- oral formulation
- prophylaxis
- treatment
- intestinal fibrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/079584 WO2023072368A1 (en) | 2021-10-25 | 2021-10-25 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
| PCT/EP2022/079666 WO2023072878A1 (en) | 2021-10-25 | 2022-10-24 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202402786B true ZA202402786B (en) | 2025-07-30 |
Family
ID=78536154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/02786A ZA202402786B (en) | 2021-10-25 | 2024-04-10 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250041228A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4312994A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024536609A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240093898A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118234489A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022374695A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230682A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312176A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005076A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023072368A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202402786B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297020A (en) | 2020-04-24 | 2022-12-01 | Dr Falk Pharma Gmbh | A systemic preparation of a pyridonone derivative related to tg2 |
| HRP20231072T1 (hr) | 2020-04-24 | 2023-12-22 | Dr. Falk Pharma Gmbh | Sustavna formulacija derivata piridinona za celijakiju |
| WO2025153465A1 (en) * | 2024-01-15 | 2025-07-24 | UCB Biopharma SRL | Method for the treatment of fibrotic-related disorder associated to ibd |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| EP2687511A1 (de) * | 2012-07-17 | 2014-01-22 | Zedira GmbH | Pyridinonderivate als Gewebetransglutaminaseinhibitoren |
-
2021
- 2021-10-25 WO PCT/EP2021/079584 patent/WO2023072368A1/en not_active Ceased
-
2022
- 2022-10-24 CN CN202280071095.9A patent/CN118234489A/zh active Pending
- 2022-10-24 JP JP2024524678A patent/JP2024536609A/ja active Pending
- 2022-10-24 US US18/704,228 patent/US20250041228A1/en active Pending
- 2022-10-24 CA CA3230682A patent/CA3230682A1/en active Pending
- 2022-10-24 EP EP22809386.0A patent/EP4312994A1/en active Pending
- 2022-10-24 MX MX2024005076A patent/MX2024005076A/es unknown
- 2022-10-24 KR KR1020247017206A patent/KR20240093898A/ko active Pending
- 2022-10-24 AU AU2022374695A patent/AU2022374695A1/en active Pending
- 2022-10-24 IL IL312176A patent/IL312176A/en unknown
- 2022-10-24 WO PCT/EP2022/079666 patent/WO2023072878A1/en not_active Ceased
-
2024
- 2024-04-10 ZA ZA2024/02786A patent/ZA202402786B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL312176A (en) | 2024-06-01 |
| JP2024536609A (ja) | 2024-10-04 |
| KR20240093898A (ko) | 2024-06-24 |
| US20250041228A1 (en) | 2025-02-06 |
| WO2023072368A1 (en) | 2023-05-04 |
| WO2023072878A1 (en) | 2023-05-04 |
| CN118234489A (zh) | 2024-06-21 |
| EP4312994A1 (en) | 2024-02-07 |
| AU2022374695A1 (en) | 2024-03-21 |
| CA3230682A1 (en) | 2023-05-04 |
| MX2024005076A (es) | 2024-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102065193B1 (ko) | 로수바스타틴 칼슘의 약학 조성물 | |
| MX2024005076A (es) | Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal. | |
| CA2761947A1 (en) | Coated pharmaceutical capsule dosage form | |
| KR20130086128A (ko) | 복용 용이성 고형 제제 | |
| TWI590835B (zh) | 含有氫嗎啡酮(hydromorphone)和納洛酮(naloxone)之藥學組成物 | |
| US12622875B2 (en) | Dosage form comprising an alkaline agent and an enteric coating layer | |
| EP3445340A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| US8299052B2 (en) | Pharmaceutical compositions and methods for improved bacterial eradication | |
| US11622938B2 (en) | Oral pharmaceutical compositions of nicotinamide | |
| CN105025883A (zh) | 右哌甲酯或其盐的调节释放的药物组合物 | |
| CA3160869C (en) | Dosage form for use in treating or preventing of a disease | |
| JP2019513801A5 (cg-RX-API-DMAC7.html) | ||
| KR20210073285A (ko) | 프로톤펌프억제제 및 모사프리드를 포함하는 유핵정 제제 | |
| JP2021503448A5 (cg-RX-API-DMAC7.html) | ||
| CN105640909B (zh) | 一种含有达比加群酯的药用组合物 | |
| RS66154B1 (sr) | Formulacije stimulansa sa tropulsnim oslobađanjem | |
| WO2017111637A1 (en) | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof | |
| Derle | Formulation Strategies for Controlled Drug Release Using MUPS Tablets: Advances and Challenges | |
| JPWO2015045604A1 (ja) | 口腔内崩壊錠 | |
| AU2006321782B2 (en) | Pharmaceutical compositions and methods for improved bacterial eradication | |
| CN110354125A (zh) | 一种治疗幽门螺杆菌感染的组合物及其制剂和用途 | |
| JP2006327943A (ja) | 経時的溶出遅延を抑制したテイストマスク錠剤 | |
| CN108472260B (zh) | 用于制备包括富马酸二甲酯的肠溶包衣颗粒的方法 | |
| CZ27703U1 (cs) | Kapsle obsahující Tamsulosin.HCI v peletách s prodlouženým uvolňováním | |
| Salve | Optimization of aqueous based film coating technique for pellets in colon specific delivery of mesalamine |